Partial and transient reduction of glycolysis by PFKFB3 blockade reduces pathological angiogenesis

Cell Metabolism

Volumn 19, Issue 1, 2014, Pages 37-48

  Schoors, Sandra ^a,b   De Bock, Katrien ^a,b   Cantelmo, Anna Rita ^a,b   Georgiadou, Maria ^a,b   Ghesquière, Bart ^a,b   Cauwenberghs, Sandra ^a,b   Kuchnio, Anna ^a,b   Wong, Brian W ^a,b   Quaegebeur, Annelies ^a,b   Goveia, Jermaine ^a,b   Bifari, Francesco ^a,b   Wang, Xingwu ^a,b   Blanco, Raquel ^c   Tembuyser, Bieke ^a,b   Cornelissen, Ivo ^a,b   Bouché, Ann ^a,b   Vinckier, Stefan ^a,b   Diaz Moralli, Santiago ^d   Gerhardt, Holger ^a,b,c   Telang, Sucheta ^e   Cascante, Marta ^d   Chesney, Jason ^e   Dewerchin, Mieke ^a,b   Carmeliet, Peter ^a,b   more..

^a UNIVERSITY OF LEUVEN   (Belgium)

^b DEPARTMENT OF PLANT SYSTEMS BIOLOGY   (Belgium)

^c IMPERIAL CANCER RESEARCH FUND   (United Kingdom)

^d UNIVERSITY OF BARCELONA   (Spain)

^e UNIVERSITY OF LOUISVILLE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PHOSPHOFRUCTOKINASE 2 FRUCTOSE 2,6 BISPHOSPHATASE 3 PROTEIN; PROTEIN; UNCLASSIFIED DRUG; VASCULOTROPIN RECEPTOR 1;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; EMBRYO; ENDOTHELIUM CELL; GENE SILENCING; GLYCOLYSIS; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; REDUCTION; RETINA; SUBRETINAL NEOVASCULARIZATION; TUMOR SPHEROID; ZEBRA FISH;

DANIO RERIO;

ANGIOGENESIS INHIBITORS; ANIMALS; CELL MOVEMENT; CELL PROLIFERATION; DISEASE MODELS, ANIMAL; GENE EXPRESSION REGULATION; GLYCOLYSIS; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; MICE; MICE, INBRED C57BL; NEOVASCULARIZATION, PATHOLOGIC; NEOVASCULARIZATION, PHYSIOLOGIC; PHOSPHOFRUCTOKINASE-2; PYRIDINES; RETINAL VESSELS; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-1; ZEBRAFISH;

EID: 84891841003     PISSN: 15504131     EISSN: 19327420     Source Type: Journal    
DOI: 10.1016/j.cmet.2013.11.008     Document Type: Article

References (37)

1. G. Cavallaro, L. Filippi, P. Bagnoli, G. La Marca, G. Cristofori, G. Raffaeli, L. Padrini, G. Araimo, M. Fumagalli, and M. Groppo et al. The pathophysiology of retinopathy of prematurity: an update of previous and recent knowledge Acta Ophthalmol. (Copenh.) 2013 10.1111/aos.12049 Published online April 26, 2013
2. J. Chesney, R. Mitchell, F. Benigni, M. Bacher, L. Spiegel, Y. Al-Abed, J.H. Han, C. Metz, and R. Bucala An inducible gene product for 6-phosphofructo-2-kinase with an AU-rich instability element: role in tumor cell glycolysis and the Warburg effect Proc. Natl. Acad. Sci. USA 96 1999 3047 3052 (Pubitemid 29148841)
3. B. Clem, S. Telang, A. Clem, A. Yalcin, J. Meier, A. Simmons, M.A. Rasku, S. Arumugam, W.L. Dean, and J. Eaton et al. Small-molecule inhibition of 6-phosphofructo-2-kinase activity suppresses glycolytic flux and tumor growth Mol. Cancer Ther. 7 2008 110 120
4. B.F. Clem, J. O'Neal, G. Tapolsky, A.L. Clem, Y. Imbert-Fernandez, D.A. Kerr 2nd, A.C. Klarer, R. Redman, D.M. Miller, and J.O. Trent et al. Targeting 6-phosphofructo-2-kinase (PFKFB3) as a therapeutic strategy against cancer Mol. Cancer Ther. 12 2013 1461 1470
5. F. Climent, F. Roset, A. Repiso, and P. Pérez de la Ossa Red cell glycolytic enzyme disorders caused by mutations: an update Cardiovasc. Hematol. Disord. Drug Targets 9 2009 95 106
6. E.P. Cummins, F. Seeballuck, S.J. Keely, N.E. Mangan, J.J. Callanan, P.G. Fallon, and C.T. Taylor The hydroxylase inhibitor dimethyloxalylglycine is protective in a murine model of colitis Gastroenterology 134 2008 156 165
7. B.A. Darlow, A.L. Ells, C.E. Gilbert, G.A. Gole, and G.E. Quinn Are we there yet? Bevacizumab therapy for retinopathy of prematurity Arch. Dis. Child. Fetal Neonatal Ed. 98 2013 F170 F174
8. K. De Bock, M. Georgiadou, and P. Carmeliet Role of endothelial cell metabolism in vessel sprouting Cell Metab. 18 2013 634 647
9. K. De Bock, M. Georgiadou, S. Schoors, A. Kuchnio, B.W. Wong, A.R. Cantelmo, A. Quaegebeur, B. Ghesquière, S. Cauwenberghs, and G. Eelen et al. Role of PFKFB3-driven glycolysis in vessel sprouting Cell 154 2013 651 663
10. J.M. Ebos, and R.S. Kerbel Antiangiogenic therapy: impact on invasion, disease progression, and metastasis Nat Rev Clin Oncol 8 2011 210 221
11. J. François, P. Eraso, and C. Gancedo Changes in the concentration of cAMP, fructose 2,6-bisphosphate and related metabolites and enzymes in Saccharomyces cerevisiae during growth on glucose Eur. J. Biochem. 164 1987 369 373 (Pubitemid 17066662)
12. I. Geudens, and H. Gerhardt Coordinating cell behaviour during blood vessel formation Development 138 2011 4569 4583
13. C. Granchi, and F. Minutolo Anticancer agents that counteract tumor glycolysis ChemMedChem 7 2012 1318 1350
14. U. Harjes, K. Bensaad, and A.L. Harris Endothelial cell metabolism and implications for cancer therapy Br. J. Cancer 107 2012 1207 1212
15. M. Hellström, L.K. Phng, J.J. Hofmann, E. Wallgard, L. Coultas, P. Lindblom, J. Alva, A.K. Nilsson, L. Karlsson, and N. Gaiano et al. Dll4 signalling through Notch1 regulates formation of tip cells during angiogenesis Nature 445 2007 776 780 (Pubitemid 46279716)
16. A. Herrero-Mendez, A. Almeida, E. Fernández, C. Maestre, S. Moncada, and J.P. Bolaños The bioenergetic and antioxidant status of neurons is controlled by continuous degradation of a key glycolytic enzyme by APC/C-Cdh1 Nat. Cell Biol. 11 2009 747 752
17. P. Hindryckx, A. Waeytens, D. Laukens, H. Peeters, J. Van Huysse, L. Ferdinande, P. Carmeliet, and M. De Vos Absence of placental growth factor blocks dextran sodium sulfate-induced colonic mucosal angiogenesis, increases mucosal hypoxia and aggravates acute colonic injury Lab. Invest. 90 2010 566 576
18. J. Krueger, D. Liu, K. Scholz, A. Zimmer, Y. Shi, C. Klein, A. Siekmann, S. Schulte-Merker, M. Cudmore, A. Ahmed, and F. le Noble Flt1 acts as a negative regulator of tip cell formation and branching morphogenesis in the zebrafish embryo Development 138 2011 2111 2120
19. G.A. Lalwani, P.J. Rosenfeld, A.E. Fung, S.R. Dubovy, S. Michels, W. Feuer, J.L. Davis, H.W. Flynn Jr., and M. Esquiabro A variable-dosing regimen with intravitreal ranibizumab for neovascular age-related macular degeneration: year 2 of the PrONTO Study Am. J. Ophthalmol. 148 2009 43 58 e1
20. J.A. Leopold, J. Walker, A.W. Scribner, B. Voetsch, Y.Y. Zhang, A.J. Loscalzo, R.C. Stanton, and J. Loscalzo Glucose-6-phosphate dehydrogenase modulates vascular endothelial growth factor-mediated angiogenesis J. Biol. Chem. 278 2003 32100 32106 (Pubitemid 37048399)
21. J.W. Locasale, and L.C. Cantley Altered metabolism in cancer BMC Biol. 8 2010 88
22. S.Y. Lunt, and M.G. Vander Heiden Aerobic glycolysis: meeting the metabolic requirements of cell proliferation Annu. Rev. Cell Dev. Biol. 27 2011 441 464
23. J.W. Miller, J. Le Couter, E.C. Strauss, and N. Ferrara Vascular endothelial growth factor a in intraocular vascular disease Ophthalmology 120 2013 106 114
24. H.S. Niranjan, N. Benakappa, K.B. Reddy, S. Nanda, and M.V. Kamath Retinopathy of prematurity promising newer modalities of treatment Indian Pediatr. 49 2012 139 143
25. M. Potente, H. Gerhardt, and P. Carmeliet Basic and therapeutic aspects of angiogenesis Cell 146 2011 873 887
26. L.E. Raez, K. Papadopoulos, A.D. Ricart, E.G. Chiorean, R.S. Dipaola, M.N. Stein, C.M. Rocha Lima, J.J. Schlesselman, K. Tolba, and V.K. Langmuir et al. A phase I dose-escalation trial of 2-deoxy-D-glucose alone or combined with docetaxel in patients with advanced solid tumors Cancer Chemother. Pharmacol. 71 2013 523 530
27. S. Rofagha, R.B. Bhisitkul, D.S. Boyer, S.R. Sadda, K. Zhang SEVEN-UP Study Group Seven-Year Outcomes in Ranibizumab-Treated Patients in ANCHOR, MARINA, and HORIZON: A Multicenter Cohort Study (SEVEN-UP) Ophthalmology 120 2013 2292 2299
28. A. Sacharidou, A.N. Stratman, and G.E. Davis Molecular mechanisms controlling vascular lumen formation in three-dimensional extracellular matrices Cells Tissues Organs (Print) 195 2012 122 143
29. A. Scott, and M. Fruttiger Oxygen-induced retinopathy: a model for vascular pathology in the retina Eye (Lond.) 24 2010 416 421
30. M. Seo, J.D. Kim, D. Neau, I. Sehgal, and Y.H. Lee Structure-based development of small molecule PFKFB3 inhibitors: a framework for potential cancer therapeutic agents targeting the Warburg effect PLoS ONE 6 2011 e24179
31. M. Singh, and N. Ferrara Modeling and predicting clinical efficacy for drugs targeting the tumor milieu Nat. Biotechnol. 30 2012 648 657
32. M.W. Stewart The expanding role of vascular endothelial growth factor inhibitors in ophthalmology Mayo Clin. Proc. 87 2012 77 88
33. S. Telang, B.F. Clem, A.C. Klarer, A.L. Clem, J.O. Trent, R. Bucala, and J. Chesney Small molecule inhibition of 6-phosphofructo-2-kinase suppresses t cell activation J. Transl. Med. 10 2012 95
34. S. Van de Veire, I. Stalmans, F. Heindryckx, H. Oura, A. Tijeras-Raballand, T. Schmidt, S. Loges, I. Albrecht, B. Jonckx, and S. Vinckier et al. Further pharmacological and genetic evidence for the efficacy of PlGF inhibition in cancer and eye disease Cell 141 2010 178 190
35. E. Van Schaftingen, B. Lederer, R. Bartrons, and H.G. Hers A kinetic study of pyrophosphate: fructose-6-phosphate phosphotransferase from potato tubers. Application to a microassay of fructose 2,6-bisphosphate Eur. J. Biochem. 129 1982 191 195
36. T.A. Wynn, A. Chawla, and J.W. Pollard Macrophage biology in development, homeostasis and disease Nature 496 2013 445 455
37. A. Yalcin, S. Telang, B. Clem, and J. Chesney Regulation of glucose metabolism by 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatases in cancer Exp. Mol. Pathol. 86 2009 174 179